Bioenvision Licenses Its Proprietary Antimicrobial Technology to Foster Corporation
01 Février 2007 - 1:00PM
Business Wire
Bioenvision, Inc. (NasdaqGM:BIVN) today announced it has entered
into a licensing arrangement with Foster Corporation to license out
exclusive rights to manufacture, market and distribute the
Company�s proprietary anti-microbial OLIGON� technology. Under the
terms of the license agreement, Bioenvision will have a revenue
sharing arrangement on future sublicenses and a royalty on all
sales by Foster, a Connecticut-based compounder of biomedical
materials. Foster also must comply with annual minimum marketing
and research and development expenditures within the first five
years of the term of the license. �We are delighted to partner with
Foster to expand the potential applications and worldwide marketing
reach for OLIGON� said David P. Luci, Executive Vice President and
General Counsel of Bioenvision. �Foster is a global market leader
in the field of medical device technology and this strategic
partnership should yield results for both companies while providing
us with the opportunity to strategically focus on the continuing
growth of our Evoltra� franchise.� Foster Corporation specializes
in developing, manufacturing and distributing biomedical materials.
Foster Corporation has served as the Company�s manufacturer of the
OLIGON� technology for several years and maintains manufacturing
expertise with biomedical materials and an extensive customer base.
Foster intends to expand the manufacturing, marketing and sales of
the OLIGON� technology primarily through its customer base that
specializes in minimally invasive tubing fabrication and special
catheter prototypes. OLIGON� is an anti-infective technology, based
on the antimicrobial properties of silver ions, that has been
incorporated into various FDA approved medical devices. The broad
spectrum activity of silver ions against bacteria, including
antibiotic-resistant strains, has been known for decades. OLIGON�
coatings have application in a wide range of devices and products,
including vascular access devices, urology catheters, pulmonary
artery catheters and thoracic devices, renal dialysis catheters and
orthopedic devices. Other potential application areas include
medical fabrics, wound dressings, laparoscopic instruments, as well
as many others. �We have worked with Foster in the past and find
their innovation and execution strategy to be an excellent fit for
Bioenvision,� said Robert Sterling, Vice President, Product
Development of Bioenvision. About Bioenvision Bioenvision's primary
focus is the acquisition, development and marketing of compounds
and technologies for the treatment of cancer. Bioenvision has a
broad pipeline of products for the treatment of cancer, including:
Evoltra�, Modrenal� (for which Bioenvision has obtained regulatory
approval for marketing in the United Kingdom for the treatment of
post-menopausal breast cancer following relapse to initial hormone
therapy), and other products. Bioenvision is also developing
anti-infective technologies, including the OLIGON� technology; an
advanced biomaterial that has been incorporated into various FDA
approved medical devices and Suvus�, an antimicrobial agent
currently in clinical development for refractory chronic hepatitis
C infection. For more information on Bioenvision please visit our
Web site at www.bioenvision.com. Certain statements contained
herein are "forward-looking" statements (as such term is defined in
the Private Securities Litigation Reform Act of 1995). Because
these statements include risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied
by such forward-looking statements include, but are not limited to:
risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's
compounds under development in particular; the potential failure of
Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure
to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers,
licenses or strategic initiatives that change Bioenvision's
business, structure or projections; the development of competing
products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in
Bioenvision's filings with the SEC. Bioenvision disclaims any
obligation to update these forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Bioenvision (NASDAQ:BIVN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Bioenvision (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Bioenvision, Inc.